GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » Net Issuance of Preferred Stock

Lukas Biomedical (ROCO:6814) Net Issuance of Preferred Stock : NT$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Lukas Biomedical's net issuance of preferred for the six months ended in Jun. 2024 was NT$0.00 Mil. The number is 0, which means that Lukas Biomedical has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Lukas Biomedical's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0.00 Mil.

Lukas Biomedical Net Issuance of Preferred Stock Historical Data

The historical data trend for Lukas Biomedical's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical Net Issuance of Preferred Stock Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Net Issuance of Preferred Stock
- - - - -

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Jun24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Lukas Biomedical Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Lukas Biomedical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
ROCO:6850 ROCO:4131 ROCO:6236 ROCO:6709 ROCO:7729 ROCO:4192 ROCO:6610 ROCO:7725 ROCO:4195 ROCO:4186 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN
Website
https://www.lukas-bio.com.tw
Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical Headlines

No Headlines